Aptevo Therapeutics Files Q1 2025 10-Q
Ticker: APVO · Form: 10-Q · Filed: May 15, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, offering, warrants
TL;DR
APVO Q1 25 10-Q filed. Shows financial health & recent offerings. Check for details.
AI Summary
Aptevo Therapeutics Inc. filed a 10-Q for the period ending March 31, 2025. The filing details financial information, including retained earnings and additional paid-in capital. It also references events such as a September 2024 registered direct offering and a warrant inducement agreement.
Why It Matters
This filing provides a snapshot of Aptevo Therapeutics' financial health and recent corporate activities, which are crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The company is in the pharmaceutical sector, which is inherently risky due to R&D costs, regulatory hurdles, and market competition.
Key Numbers
- 0.02 — Other Liabilities Current (Represents a current liability item on the balance sheet.)
- 0.027 — Other Liabilities Current (Represents a current liability item on the balance sheet.)
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250515 (date) — Filing date
- 001-37746 (company) — SEC File Number
- September 2024 Registered Direct Offering (event) — Mentioned subsequent event
- Warrant Inducement Agreement (event) — Mentioned subsequent event
FAQ
What were the key financial metrics reported for the quarter ending March 31, 2025?
The filing references financial data points such as 'RetainedEarningsMember' and 'AdditionalPaidInCapitalMember' for periods including March 31, 2025, and January 1, 2024, to March 31, 2024.
What significant corporate actions or events are mentioned as subsequent events?
Subsequent events mentioned include the 'September2024RegisteredDirectOfferingMember' and the 'SalesAgreementAndTheRegistrationStatementMember' on May 14, 2025, and the 'WarrantInducementAgreementMember'.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the company's primary business classification?
The company is classified under Pharmaceutical Preparations [2834].
What is the company's business address?
The business address is 2401 4TH AVE., SUITE 1050, SEATTLE, WA 98121.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Aptevo Therapeutics Inc. (APVO).